Endothelial t-PA release is impaired in overweight and obese adults but can be improved with regular aerobic exercise

American Journal of Physiology - Endocrinology and Metabolism

Volumn 289, Issue 5 52-5, 2005, Pages

  Van Guilder, Gary P ^a   Hoetzer, Greta L ^a   Smith, Derek T ^a   Irmiger, Heather M ^a   Greiner, Jared J ^a   Stauffer, Brian L ^a,b   DeSouza, Christopher A ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Endothelium; Fibrinolysis; Tissue type plasminogen activator

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AEROBIC CAPACITY; ARTICLE; ATHEROSCLEROSIS; ENDOTHELIUM CELL; EXERCISE; FEMALE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; SITTING; THROMBOSIS; VASCULAR ENDOTHELIUM; WEIGHT REDUCTION;

BLOOD GLUCOSE; BODY WEIGHT; C-REACTIVE PROTEIN; CHOLESTEROL; CROSS-SECTIONAL STUDIES; ENDOTHELIUM, VASCULAR; EXERCISE; FEMALE; HUMANS; INSULIN; INTERLEUKIN-18; INTERLEUKIN-6; MALE; MIDDLE AGED; OBESITY; TISSUE PLASMINOGEN ACTIVATOR; TRIGLYCERIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 27144551648     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.00072.2005     Document Type: Article

References (52)

1. American Diabetes Association. Clinical practice recommendations 2004. Diabetes Care 27: S1-S150, 2004.
2. Blair SN and Brodney S. Effects of physical inactivity and obesity on morbidity and mortality: current evidence and research issues. Med Sci Sports Exerc 31: S646-S662, 1999.
3. Blankenberg S, Luc G, Ducimetiere P, Arveiler D, Ferrieres J, Amouyel P, Evans A, Cambien F, and Tiret L. Interleukin-18 and the risk of coronary heart disease in European men: the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation 108: 2453-2459, 2003.
4. Brommer EJ. The level of extrinsic plasminogen activator (t-PA) during clotting as a determinant of the rate of fibrinolysis: inefficiency of activators added afterwards. Thromb Res 34: 109-115, 1984.
5. Caballero AE. Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease. Obes Res 11: 1278-1289, 2003.
6. Carmeliet P, Schoonjans L, Kieckens L, Ream B, Degan J, Bronson R, De Vos R, van den Oord JJ, Collen D, and Mulligan RC. Physiological consequences of loss of plasminogen activator gene function in mice. Nature 368: 419-424, 1994.
7. Caterson ID, Hubbard V, Bray GA, Grunstein R, Hansen BC, Hong Y, Labarthe D, Seidell JC, and Smith SC Jr. Prevention Conference VII: Obesity, a worldwide epidemic related to heart disease and stroke: Group III: worldwide comorbidities of obesity. Circulation 110: e476-e483, 2004.
8. Chaplin H and Mollison P. Correction of plasma trapped in the red cell column of hematocrit. Blood 7: 1227-1238, 1952.
9. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT, and Roccella EJ. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 289: 2560-2572, 2003.
10. Christie PD, Edelberg JM, Picard MH, Foulkes AS, Mamuya W, Weiler-Guettler H, Rubin RH, Gilbert P, and Rosenberg RD. A murine model of myocardial microvascular thrombosis. J Clin Invest 10: 533-539, 1999.
11. DeSouza CA, Shapiro LF, Clevenger CM, Dinenno FA, Monahan KD, Tanaka H, and Seals DR. Regular aerobic exercise prevents and restores the age-related decline in endothelium-dependent vasodilation in healthy men. Circulation 102: 1351-1357, 2000.
12. Diamond SL, Eskin SG, and McIntire LV. Fluid flow stimulates tissue plasminogen secretion by cultured human endothelial cells. Science 243: 1483-1485, 1989.
13. Diamond SL, Sharefkin JB, Dieffenbach C, Fraiser-Scott K, McIntire LV, and Eskin SG. Tissue plasminogen activator messenger RNA levels increase in cultured human endothelial cells exposed to laminar shear stress. J Cell Physiol 143: 364-371, 1990.
14. Emeis JJ. The control of t-PA and PAI-1 secretion from the vessel wall. Vasc Med 6: 153-166, 1995.
15. Engstrom G, Hedblad B, Stavenow L, Jonsson S, Lind P, Janzon L, and Lindgarde F. Incidence of obesity-associated cardiovascular disease is related to inflammation-sensitive plasma proteins: a population based cohort study. Arterioscler Thromb Vasc Biol 24: 1498-1502, 2004.
16. Eriksson P, Reynisdottir S, Lonnqvist F, Stemme V, Hamsten A, and Armer P. Adipose tissue secretion of plasminogen activator inhibitor-1 in nonobese and obese individuals. Diabetologia 41: 65-71, 1998.
17. Farrell SW, Cheng YJ, and Blair SN. Prevalence of the metabolic sydrome across cardiorespiratory fitness levels in women. Obes Res 12: 824-830, 2004.
18. Fedder DO, Koro CE, and L'Italien GJ. New National Cholesterol Education Program III guidelines for primary prevention lipid-lowering drug therapy: projected impact on the size, sex, and age distribution of the treatment-eligible population. Circulation 105: 152-156, 2002.
19. Feng YH and Hart G. In vitro oxidative damage to tissue-type plasminogen activator: a selective modification of the biological functions. Cardiovasc Res 30: 255-261, 1995.
20. Flegal KM, Carroll MD, Ogden CL, and Johnson CL. Prevalence and trends in obesity among US adults. JAMA 288: 1723-1727, 2003.
21. Fox KA, Robinson AK, Knabb RM, Rosamond TL, Sobel BE, and Bergman SR. Prevention of coronary thrombosis with subthrombolytic doses of tissue-type plasminogen activator. Circulation 72: 1346-1354, 1985.
22. Hoetzer GL, Stauffer BL, Greiner JJ, Casas Y, Smith DT, and DeSouza CA. Influence of oral contraceptive use on endothelial t-PA release in healthy premenopausal women. Am J Physiol Endocrinol Metab 284: E90-E95, 2003.
23. Hoetzer GL, Stauffer BL, Irmiger HM, Ng M, Smith DT, and De-Souza CA. Acute and chronic effects of oestrogen on endothelial tissue-type plasminogen activator release in postmenopausal women. J Physiol 551: 721-728, 2003.
24. Hoffmeister HM, Jur M, Ruf-Lehman M, Helber U, Heller W, and Seipel L. Endothelial tissue-type plasminogen activator release in coronary heart disease. Transient reduction in endothelial fibrinolytic reserve in patients with unstable angina pectoris or acute myocardial infarction. J Am Coll Cardiol 31: 547-551, 1998.
25. Hrafnkelsdottir T, Wall U, Jern C, and Jern S. Impaired capacity for endogenous fibrinolysis in essential hypertension. Lancet 352: 1597-1598, 1998.
26. Jern S, Wall U, Bergbrant A, Selin-Sjogren L, and Jern C. Endothelium-dependent vasodilation and tissue-type plasminogen activator release in borderline hypertension. Arterioscler Thromb 17: 3376-3383, 1997.
27. Katzmarzyk PT, Church TS, and Blair SN. Cardiorespiratory fitness attenuates the effects of metabolic syndrome on all-cause and cardiovascular disease mortality in men. Arch Intern Med 164: 1092-1097, 2004.
28. Kooistra T, Schrauwen Y, Artis J, and Emeis JJ. Regulation of endothelial cell t-PA synthesis and release. Int J Hematol 59: 233-255, 1994.
29. Kugiyama K, Sakamoto T, Misumi I, Sugiyama S, Ohgushi M, Ogawa H, Horiguchi M, and Yasue H. Transferable lipids in oxidized low-density lipoprotein stimulate plasminogen activator inhibitor-1 and inhibit tissue-type plasminogen activator release from endothelial cells. Circ Res 73: 335-343, 1993.
30. Landin K, Stigendal L, Eriksson E, Krotkiewski M, Risberg B, Tengborn L, and Smith U. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. Metabolism 39: 1044-1048, 1990.
31. Levine GN, Keaney JF, and Vita JA. Cholesterol reduction in cardiovascular disease: clinical benefits and possible mechanisms. JAMA 332: 512-521, 1995.
32. Lohman TG, Roche AF, and Mortorell R. Arthropometric Standardization Reference Manual. Champaign, IL: Human Kinetics, 1988.
33. Macko RF, Ameriso SF, Gruber A, Griffin JH, Fernandez JA, Brandt R, Quismorio FP Jr., Weiner JM, and Fisher M. Impairments of the protein C system and fibrinolysis in infection-associated stroke. Stroke 27: 2005-2011, 1996.
34. Mathews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, and Turner RC. Homeostasis model assessment: insulin resistance and B-cell function from plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419, 1985.
35. McGill HC, McMahan CA, Herderick EE, Zieske AW, Malcom GT, Tracy RE, and Strong JP. Obesity accelerates the progression of coronary atherosclerosis in young men. Circulation 105: 2712-2718, 2002.
36. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, and Marks JS. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 289: 76-79, 2003.
37. Muldowney JA III and Vaughan DE. Tissue-type plasminogen activator release: new frontiers in endothelial function. J Am Coll Cardiol 40: 967-969, 2002.
38. Must A, Spadano J, Coakley EH, Field AE, Colditz G, and Dietz WH. The disease burden associated with overweight and obesity. JAMA 282: 1523-1529, 1999.
39. National Institutes of Health. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report. Bethesda, MD: National Heart, Lung, and Blood Institute and National Institute of Diabetes and Digestive and Kidney Diseases, 1998.
40. Newby DE, Wright RA, Labinjoh C, Ludlam CA, Fox KA, Boon NA, and Webb DJ. Endothelial dysfunction, impaired endogenous fibrinolysis, and cigarette smoking: a mechanism for arterial thrombosis and myocardial infarction. Circulation 99: 1411-1415, 1999.
41. Parmer RJ, Mahata M, Mahata S, Sebald MT, O'Connor DT, and Miles LA. Tissue plasminogen activator (t-PA) is targeted to the regulated secretory pathway. J Biol Chem 272: 1976-1982, 1997.
42. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC, Taubert K, Tracy RP, and Vinicor F. Markers of inflammation and cardiovascular disease: application to clinical and public practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107: 499-511, 2003.
43. Perticone F, Ceravolo R, Candigliota M, Ventura G, Iacopino S, Sinopoli F, and Mattioli PL. Obesity and body fat distribution induce endothelial dysfunction by bxidative stress: protective effect of vitamin C. Diabetes 50: 159-165, 2001.
44. Quyyumi AA. Endothelial function in health and disease: new insights into the genesis of cardiovascular disease. Am J Med 105: 32S-39S, 1998.
45. Rea TD, Heckbert SR, Kaplan RC, Psaty BM, Smith NL, Lemaitre RN, and Lin D. Body mass index and the risk of recurrent coronary events following acute myocardial infarction. Am J Cardiol 88: 467-472, 2001.
46. Rosito GA, D'Agostino RB, Massaro J, Lipinska I, Mittleman MA, Sutherland P, Wilson PW, Levy D, Muller JE, and Tofler GH. Association between obesity and a prothrombotic state: the Framingham Offspring Study. Thromb Haemost 91: 683-689, 2004.
47. Smith DT, Hoetzer GL, Greiner JJ, Stauffer BL, and DeSouza CA. Effects of ageing and regular aerobic exercise on endothelial fibrinolytic capacity in humans. J Physiol 546: 289-298, 2003.
48. Tanaka H, Dinenno FA, Monahan KD, Clevenger CM, DeSouza CA, and Seals DR. Aging, habitual exercise and dynamic arterial compliance. Circulation 102: 1270-1275, 2000.
49. 49a. Van den Eijnden-Schrauwen Y, Kooistra T, de Vries RE, and Emeis JJ. Studies on the acute release of tissue-type plasminogen activator from human endothelial cells in vitro and in rats in vitro: evidence for a dynamic storage pool. Blood 85: 3510-3517, 1995.
50. Walker SP, Rimm EB, Ascherio A, Kawachi I, Stampfer MJ, and Willet WC. Body size and fat distribution as predictors of stroke among US men. Am J Epidemiol 144: 1143-1150, 1996.
51. Willerson JT and Ridker PM. Inflammation as a cardiovascular risk factor. Circulation 109, Suppl I: II2-II10, 2004.
52. Williams IL, Wheatcroft SB, Shah AM, and Kearney MT. Obesity, atherosclerosis and vascular endothelium: mechanisms of reduced nitric oxide bioavailability in obese humans. Int J Obes 26: 754-764, 2002.